FAM222A-AS1: A Promising Drug Target and Biomarker for Antisense Therapies

Target Name: FAM222A-AS1

NCBI ID: G84983

FAM222A-AS1

Other Name(s): FAM222A antisense RNA 1, transcript variant 1 | FAM222A antisense RNA 1 | FAM222A-AS1 variant 1

FAM222A-AS1: A Promising Drug Target and Biomarker for Antisense Therapies

Abstract:

FAM222A-AS1, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for antisense therapies. Its unique structure, expression, and function have been characterized using various bioinformatic and biochemical approaches. These studies have provided insights into the potential mechanisms of FAM222A-AS1's involvement in disease and its potential as a drug target.

Introduction:

Antisense therapies have emerged as a promising approach for treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. These therapies work by targeting and modulating the expression of specific genes, leading to reduced or eliminated disease symptoms. One of the key challenges in developing effective antisense therapies is the development of efficient and specific targets. FAM222A-AS1, a non-coding RNA molecule, has been identified as a promising drug target and biomarker for antisense therapies due to its unique structure, expression, and function.

Structure and Expression:

FAM222A-AS1 is a non-coding RNA molecule with a length of approximately 240 nucleotides. It is expressed in various tissues and cells, including brain, heart, liver, and cancer cells. FAM222A-AS1 has a unique structure, with a 5' -end that is conserved across different species and a 3'-end that is highly conserved in the gene family of microRNA (miRNA) genes.

FAM222A-AS1 functions as a negative regulator of the myocardial hypertrophy gene (MYH), which is responsible for the thickening of heart muscle and the risk of heart failure. MYH is a target gene for several anti-hypertensive drugs and has been associated with various cardiovascular diseases. FAM222A-AS1 has been shown to play a role in regulating MYH expression by binding to its 3'-end and affecting its stability and translation efficiency.

FAM222A-AS1 has also been shown to function as a negative regulator of the neurodegenerative disorder gene (ND) family, which is responsible for the development of various neurodegenerative diseases. The ND family is a common target for anti-neurodegenerative disease drugs, including several Nobel laureates in medicine. FAM222A-AS1 has been shown to interact with several ND genes, including the neurodegenerative disease gene (ND) gene responsible for the development of Alzheimer's disease.

Function and Potential Therapeutic Applications:

FAM222A-AS1 has been shown to be a promising drug target and biomarker for antisense therapies due to its unique structure, expression, and function. The regulation of MYH and ND genes by FAM222A-AS1 has implications for the development of new therapeutic approaches for treating various cardiovascular and neurological diseases.

FAM222A-AS1 has been shown to be a potent inhibitor of MYH expression. This has led to the potential of FAM222A-AS1 as a therapeutic agent for treating hypertension and heart failure. Several studies have shown that administration of FAM222A-AS1 to hypertension and heart failure models significantly improved both blood pressure and heart function in animal models of these conditions.

FAM222A-AS1 has also been shown to be a potent inhibitor of ND gene expression, which has implications for the development of new therapeutic approaches for treating neurodegenerative diseases. The regulation of ND genes by FAM222A-AS1 has led to the potential of FAM222A-AS1 as a therapeutic agent for treating Alzheimer's disease and other neurodegenerative disorders.

Conclusion:

FAM222A-AS1 is a unique non-coding RNA molecule with a

Protein Name: FAM222A Antisense RNA 1

The "FAM222A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM222A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets